A case of T-prolymphocytic leukemia harboring RAS mutation
Annals of Hematology · 09.04.2026 · 105 (5)
DOI: 10.1007/s00277-026-06986-2 ↗Kurz gefasst
Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 09.04.2026. Verfasst von Salvatore Perrone und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, S.M. Goretti Hospital, Polo Universitario Pontino, Latina, Italy. Hauptthemen laut MEDLINE: Leukemia, Prolymphocytic, T-Cell, Proto-Oncogene Proteins p21(ras), Mutation. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Roma La Sapienza.
Abstract (Originalsprache)
The text reports the clinical case of a 61-year-old woman with a long history of generalized pruritus who was eventually diagnosed with T-cell prolymphocytic leukemia (T-PLL), a rare and aggressive T-cell lymphoproliferative disorder. At presentation, the patient had fever, skin lesions, lymphocytosis, thrombocytopenia, coagulation abnormalities, and marked splenomegaly without lymphadenopathy. Morphological, immunophenotypic, and histological analyses of peripheral blood and bone marrow revealed diffuse infiltration by mature T lymphocytes with strong TCL1 expression, and T-cell receptor gene rearrangement confirmed clonality, supporting the diagnosis of T-PLL. The patient initially received bendamustine chemotherapy, which failed to induce a response. Second-line treatment with the anti-CD52 monoclonal antibody alemtuzumab was subsequently initiated, but the disease proved refractory, with persistent bone marrow involvement, worsening cytopenias, disease progression, and clinical deterioration. As a result, alemtuzumab was discontinued and the patient was transitioned to palliative care. A particularly notable finding was the detection, by next-generation sequencing, of a pathogenic KRAS G12A mutation, which has not previously been reported in T-PLL. This mutation was identified incidentally using a myeloid-targeted NGS panel. The finding broadens the known mutational spectrum of T-PLL and suggests that activation of the RAS signaling pathway may represent an alternative oncogenic mechanism beyond the canonical TCL1 and JAK–STAT pathways. We suggest that investigating for KRAS mutations in additional T-PLL cases may be beneficial to explore this pathogenetic pathway and could open new avenues for future targeted therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, S.M. Goretti Hospital, Polo Universitario Pontino, Latina, Italy.
- Department of Translational Precision Medicine, University La Sapienza, Rome, Italy. giada.pacitto@uniroma1.it.
- Department of Translational Precision Medicine, University La Sapienza, Rome, Italy.
- Division of Medical Genetics, Department of Experimental Medicine, San Camillo-Forlanini Hospital, Sapienza University, Rome, Italy.
- Department of Biomedicine and Prevention, Tor Vergata University, Rome, Italy.
- Department of Clinical and Molecular Medicine, School of Medicine and Psychology, Sapienza University, Sant'Andrea University Hospital, Rome, Italy.
Förderung
- Università degli Studi di Roma La Sapienza
Zitieren
APA
Perrone, S., Pacitto, G., Tirnetta, A., Mulargia, C., Angelitti, M. R., Corbingi, A., Ortu La Barbera, E., Fabiani, E., Voso, M. T., & Di Napoli, A. (2026). A case of T-prolymphocytic leukemia harboring RAS mutation. Annals of Hematology, 105(5). https://doi.org/10.1007/s00277-026-06986-2
Vancouver
Perrone S, Pacitto G, Tirnetta A, Mulargia C, Angelitti MR, Corbingi A, et al. A case of T-prolymphocytic leukemia harboring RAS mutation. Annals of Hematology. 2026;105(5). doi:10.1007/s00277-026-06986-2
BibTeX
@article{Perrone2026,
author = {Perrone, Salvatore and Pacitto, Giada and Tirnetta, Alessia and Mulargia, Claudia and Angelitti, Maria Rosaria and Corbingi, Andrea and Ortu La Barbera, Elettra and Fabiani, Emiliano and Voso, Maria Teresa and Di Napoli, Arianna},
title = {A case of T-prolymphocytic leukemia harboring RAS mutation},
journal = {Annals of Hematology},
year = {2026},
volume = {105},
number = {5},
doi = {10.1007/s00277-026-06986-2}
}
EUVIMED